Frovatriptan is a Medicine belongs to antimigraine drugs group whose information about Brand can be referenced from   Book : Martindale    Page : 676   Edition : 38  

  ►   Brandname : Migard, Frova, Allegro
  ►  Strength : Tablet with 2.5 mg. 

Reference of this Medicine for its Strength can be taken from   Book : Basic & Clinical pharmacology    Page : 292   Edition : 12  
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral
Reference :-   Book : Martindale    Page : 677   Edition : 37  

Dosing of Medicine differ in Adult & Pediatrics ↓

Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 Headache phase of migraine attacks Oral 2.5 mg Tablet Given for acute treatment of the headache.

Ref :-  Book : Martindale    Page : 677   Edition : 37  



Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Management of acute migraine headaches Oral 2.5 mg

Ref :- Book : Nelson's textbook of Pediatrics    Page : 2044   Edition : 19  
►  Side Effect : Dizziness, Flushing, Nausea, Chest pain, Serious adverse effects: (, Hypertensive crisis, Stroke, Coronary artery spasm, Seizure, Myocardial infarction or ischemia, )
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 223   Edition : 3.  

►  Drug Interaction : Drug interaction of Frovatriptan is with , selective serotonin reuptake inhibitors, Selective nonadrenaline reuptake inhibitors, ,  Methysergide
Ref :-   Book : Martindale    Page : 676,681   Edition : 38.  


  ►    Mechanism of Drug Drug Interaction :  Fluvoxamine is a potent inhibitor of the cytochrome P450 isoenzyme CYP1A2 and has been shown to increase the blood levels of frovatriptan by 27 to 49%. It should not be given with ergotamine or related compounds (including methysergide) since there is an increased risk of vasospastic reactions. In addition, a delay is advised before starting a serotonin (5-HT1) agonist in patients who have been receiving ergotamine or related compounds: sumatriptan, frovatriptan, should not be given until at least 24 hours after stopping the use of preparations containing ergotamine. Conversely, ergotamine should not be given until 6 hours after stopping these drugs or at least 24 hours in the case of frovatriptan. Serotonin (5- HT1) agonists should not be given together. There have been rare reports of serotonin syndrome associated with the use of triptan serotonin (5-HT1) agonists with SSRIs or serotonin and noradrenaline reuptake inhibitors.
Ref :-   Book : Martindale    Page : 676,681   Edition : 38.  


►  Contraindication : Ergot agent or serotonin 5-HT1 agonist within 24 hours, Concomitant use of MAO inhibitor, Ischemic cardiac, Cerebrovascular or peripheral vascular syndromes, Uncontrolled hypertension
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 223   Edition : 3.  
  ►  Mechanism of Action :   It is a selective serotonin agonist that acts at 5-HT1 receptors and produces vasoconstriction of cranial arteries.
Ref :-   Book : Martindale    Page : 681   Edition : 37.  

Pathway of DIETARY Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- NA


DIETARY Substance Interactions


​   ► This Medicine interact with :- NA



ContraIndication DIETARY Substance


​   ► This Medicine contraindicate with :- NA

►   Route of Elimination :   Fecal, Renal
Ref :-   Book : Martindale    Page : 677   Edition : 37.  

►    Plasma Half-life :   Min value :-   26 hours,    Max value :-   NA
Ref :-   Book : Martindale    Page : 677   Edition : 37.  

►    Peak Plasma Concentration :   Min value :-   2 hours,    Max value :-   4 hours.  
Ref :-   Book : Martindale    Page : 676   Edition : 37.